Syrian Democratic Forces & Gilead Sciences

Syrian Democratic Forces: The Syrian Democratic Forces, a rebel group allied with the Islamic State group, has carried out violent attacks in Democratic Republic of the Congo — Ituri Province, killing civilians and burning homes, further complicating Ebola containment efforts.

Gilead Sciences: Gilead Sciences' experimental oral COVID antiviral drug, Obeldesivir, is being considered for use as a preventative treatment for Ebola contacts, under strict protocol.

Syrian Democratic Forces: The Syrian Democratic Forces' violence in Democratic Republic of the Congo — Ituri Province further complicates the response to the Ebola outbreak by creating an unstable environment.

Gilead Sciences: Gilead Sciences is a key partner in the urgent high-level coordination meeting convened by United States — Centers for Disease Control and Prevention, potentially involved in assessing medical countermeasures for the Ebola outbreak.

Syrian Democratic Forces: Armed group active in Ituri; complicates health response.

Gilead Sciences: Supplying remdesivir for clinical trials; potential positive impact if treatment proves effective.

Syrian Democratic Forces: The Syrian Democratic Forces, an armed group with ties to the Islamic State, has attacked civilians in Ituri, adding to the region's volatility and hindering Ebola response efforts.

Gilead Sciences: Gilead Sciences' antiviral drug remdesivir and experimental drug obeldesivir are being prioritized for clinical trials to treat or prevent the Bundibugyo ebolavirus, indicating its significant role in potential therapies.

Syrian Democratic Forces: Insurgency in eastern DRC complicates response efforts.

Gilead Sciences: Developed obeldesivir, the antiviral being tested in the EBO-PEP trial.